Certera Vice President and Global Head of Value and Access Oliver Leatham in a recent article published in the European Pharmaceutical Manufacturer looks at the complex issue of valuation for new drugs.
“How do you assign a value to saving someone’s life? Then, how do you pay the bill? Those are questions that manufacturers and health authorities are increasingly being asked to answer as pharmaceutical companies attempt to gain regulatory approval and subsequent reimbursement for innovative and, in some cases, curative new therapies; products with limited evidence and small patient populations,” he writes.
To read the full article, click here.